It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Cushing's syndrome is associated with multisystem morbidity and, when suboptimally
treated, increased mortality. Medical therapy is an option for patients if surgery is not …

Substantial advances have been made recently in the pathobiology of pituitary tumors.
Similar to many other endocrine tumors, over the last few years we have recognized the role …

Histone deacetylase inhibitors (HDIs) are a class of prominent epigenetic drugs that are
currently being tested in hundreds of clinical trials against a variety of diseases. A few …

Endogenous Cushing's syndrome (CS) is associated with morbidities (diabetes,
hypertension, clotting disorders) and shortens life because of infections, pulmonary …

Pituitary adenomas are benign tumours comprising approximately 16% of all primary cranial
neoplasms. Functioning pituitary adenomas (prolactinomas, somatotroph, corticotroph …

Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …

Cushing's disease caused due to adrenocorticotropic hormone (ACTH)-secreting pituitary
adenomas (ACTHomas) leads to hypercortisolemia, resulting in increased morbidity and …

Thymic-derived naturally occurring regulatory T cells (tTreg) are crucial for maintaining
peripheral immune homeostasis. They play a crucial role in preventing autoimmunity and …